Tarian Pharma is a privately owned clinical-stage pharmaceutical company developing targeted solutions to prevent severe skin toxicities associated with cancer treatment. These toxicities are a major cause of dose reductions, treatment delays, lower patient adherence, and reduced quality of life. By addressing this critical unmet need, Tarian aims to improve treatment outcomes and strengthen the value of oncology therapies.
TAR-0520 (Tarian Gel) is a topical extended-release formulation of brimonidine tartrate designed to help prevent treatment-related skin toxicities. It works through localized, transient vasoconstriction, mimicking the protective effect of cooling devices. TAR-0520 is protected by multiple patents covering both composition of matter and method of use.
Tarian Gel is currently being investigated in three clinical phase 2 studies:
1. EGFR-induced folliculitis in metastatic colorectal cancer,
2. Taxane-induced peripheral neuropathy in breast cancer,
3. Capecitabine-induced Hand and Foot syndrome in colorectal and breast cancer. Results of these studies are expected in S1 2027.
We envision a future where oncology supportive care is proactive, science-driven, and patient-centered, helping patients complete treatment with fewer dermatological side effects and a better quality of life. Patients undergoing cancer treatment face more than the disease itself: they may also experience skin toxicities that affect comfort, self-esteem, daily life, and the ability to continue treatment as planned.
We developed Tarian Gel as a topical protective approach designed to help reduce skin toxicities, support quality of life, and promote treatment continuity. Simple, practical, and designed around patients, it reflects Tarian’s commitment to protecting what matters throughout cancer treatment.
Tarian Gel is designed as a simple, adaptable topical treatment that can be integrated into oncology care pathways without adding unnecessary burden for patients or clinicians.
Scientifically developed to help prevent severe treatment-related skin toxicities while supporting continuity of cancer treatment.
A simple, portable application designed to fit naturally into patients’ daily routines.
Developed through more than 200 formulation prototypes and supported by oncology expertise, preclinical development, and expert clinical evaluation.
Up to 90% of patients undergoing chemotherapy or targeted therapies may develop skin side effects such as dryness, rashes, or irritation, affecting physical comfort, confidence, daily life, and treatment adherence. 1
Up to 30% of cancer patients consider modifying or discontinuing treatment because of skin-related toxicities. Despite their frequency and clinical importance, these toxicities remain an under-addressed aspect of oncology supportive care.
